BioProcess360 Partners launch dedicated Life Sciences investment fund to grow emerging bioprocessing tools and technologies

Core Insights - BioProcess360 Partners has launched a new investment fund aimed at supporting businesses in the bioprocessing sector, particularly focusing on traditional monoclonal antibodies (mAbs) and newer drug modalities [1] - The fund combines investment capital with support from industry experts and connections to leading global biopharmaceutical companies to address R&D and commercialization challenges [1][2] - The founding partners bring significant experience, including Chris Major's leadership in the Purolite Bioprocessing division, which was acquired for $3.7 billion by Ecolab in 2021 [1] Investment Focus - The fund emphasizes a hands-on, collaborative approach to bioprocessing, filling a market gap for specialized operating partners in this field [3] - BioProcess360 Partners is positioned to make quick investments due to its deep expertise in bioprocessing, allowing for rapid support to businesses [3] Expert Support - The team consists of 14 subject matter experts who provide strategic, operational, and technical guidance across various areas, including R&D, manufacturing, regulatory compliance, and commercial operations [2] - The goal is to offer practical, hands-on support to innovative bioprocessing technologies, ultimately benefiting patients [5] Industry Challenges - Businesses in the bioprocessing space often face challenges due to a lack of access to industry experience and knowledge necessary for navigating growth challenges [4] - BioProcess360 Partners aims to mitigate these challenges by providing direct access to experienced industry experts [5]